<DOC>
	<DOC>NCT00725374</DOC>
	<brief_summary>The primary purpose of this study is to compare changes in the expression of the proliferation marker Ki-67 in malignant breast tissue after treatment with tibolone or placebo in postmenopausal women who need to undergo surgery for primary breast cancer</brief_summary>
	<brief_title>A Study to Investigate the Effects of Tibolone (LivialÂ®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tibolone</mesh_term>
	<criteria>postmenopausal women of any age requiring surgery for early invasive primary breast cancer (clinically stage I or II; T1T3; N01; M0), with estrogen receptorpositive tumor(s) body mass index between 18 and 2 kg/m2, inclusive must be willing to give voluntary written informed consent. healthy subjects</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>